Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML).

被引：0
|
作者：
Nunnery, Sara [1 ]
Wang, Dorothy [1 ]
Tan, Marisela [1 ]
Fong, Richard [1 ]
Lo, Mimi Ming [1 ]
Olin, Rebecca L. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e19009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19009
引用
收藏
页数：2
相关论文
共 50 条
  • [31] MITOZANTRONE AND HIGH-DOSE CYTARABINE IN REFRACTORY ADULT ACUTE MYELOID-LEUKEMIA
    HIDDEMANN, W
    KREUTZMANN, H
    LUDWIG, WD
    AUL, HC
    DONHUIJSENANT, R
    LENGFELDER, E
    BUCHNER, T
    LANCET, 1985, 2 (8453): : 508 - 509
  • [32] CLOFARABINE IN COMBINATION WITH CYTARABINE (ARA-C) FOR TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN ADULT PATIENTS
    Malato, A.
    Santoro, A.
    Magrin, S.
    Felice, R.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    HAEMATOLOGICA, 2012, 97 : 502 - 503
  • [33] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Naqvi, Kiran
    Ravandi, Farhad
    Kantarjian, Hagop
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Thomas, Deborah A.
    Koller, Charles Asa
    Konopleva, Marina
    Byrd, Anna
    Kwari, Monica
    Faderl, Stefan
    BLOOD, 2010, 116 (21) : 464 - 465
  • [34] Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia
    Zhong, Sharon
    Kurish, Heena
    Walchack, Robert
    Li, Hong
    Edwards, Jessi
    Singh, Abhay
    Advani, Anjali
    LEUKEMIA RESEARCH, 2024, 139
  • [35] Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes
    Roberts, Daniel A.
    Wadleigh, Martha
    McDonnell, Anne M.
    DeAngelo, Daniel J.
    Stone, Richard M.
    Steensma, David P.
    LEUKEMIA RESEARCH, 2015, 39 (02) : 204 - 210
  • [36] Limited phase I trial of sequential high dose cytarabine and clofarabine (HiDAC→CLOF) in relapsed or refractory acute myeloid leukemia.
    Powell, Bayard L.
    Lovato, James
    Kimbrough, Claire
    Lyerly, Susan
    Galloway-Daniels, Sonya
    Motley, Cathy
    Harrelson, Robin
    Keung, Yi Kong
    Thakuri, Mohan C.
    Molnar, Istvan
    Levitan, Denise
    Hurd, David Duane
    BLOOD, 2006, 108 (11) : 221B - 221B
  • [37] High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
    Cortes, J
    Estey, E
    O'Brien, S
    Giles, F
    Shen, Y
    Koller, C
    Beran, M
    Thomas, D
    Keating, M
    Kantarjian, H
    CANCER, 2001, 92 (01) : 7 - 14
  • [38] Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia
    Deisseroth, Albert
    Farrell, Ann
    Justice, Robert
    Kane, Robert
    Sridhara, Rajeshwari
    Chen, Huanyu
    He, Kun
    Pazdur, Richard
    BLOOD, 2010, 115 (02) : 430 - 430
  • [39] Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML)
    Stuart, R. K.
    Stockerl-Goldstein, K.
    Cooper, M.
    Devetten, M.
    Herzig, R.
    Medeiros, B.
    Schiller, G.
    Wei, A.
    Acton, G.
    Rizzieri, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] High-dose cytarabine induction for acute myeloid leukemia
    Shepherd, JD
    Barnett, MJ
    Phillips, GL
    BLOOD, 1996, 88 (02) : 754 - 754
12345